Given the patient’s high NGS HER-2 CN expression, PD-L1 CPS < 1, and MSS status, we opted for a treatment regimen combining cadonilimab, trastuzumab, and chemotherapy for this GC patient. Here, ERBB2 is linked to gastric cancer.